Session Chair Profile

Ph.D., Chief Business Development Officer, Adaptive Biotechnologies

Biography
Dr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group at Adaptive. Sharon oversees the use of the company’s immune medicine platform for novel drug discovery, including TCR discovery to inform next-generation cellular therapy, antibody discovery, and vaccines. Before joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and technology services company. Sharon came to Elsevier from Capgemini, where she held a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.

Talk
Next-generation Supply Chain For Cell & Gene Therapies
For truly personalized cell and gene therapies to become standard of care, we must continue to leverage and successfully implement advances in science, technology, automation and digitization to scale the process and shorten the time it takes to get lifesaving medicines to patients in need.


 Session Abstract – PMWC 2022 Silicon Valley


For truly personalized cell and gene therapies to become standard of care, we must continue to leverage and successfully implement advances in science, technology, automation and digitization to scale the process and shorten the time it takes to get lifesaving medicines to patients in need.